Information:
Error:
Keywords
Drugs, Investigational ×
- Clinical Trial (203)
- Vital Signs (78)
- Pharmacokinetics (58)
- Laboratories (50)
- Electrocardiogram (ECG) (41)
- Clinical Trial, Phase I (40)
- Pulmonary Medicine (34)
- Medical Oncology (25)
- Pulmonary Disease, Chronic Obstructive (24)
- Anxiety Disorders (22)
- Paroxetine (21)
- Depressive Disorder (21)
- Pharmaceutical Preparations (21)
- Hematology (21)
- Respiratory Function Tests (20)
- Neurology (20)
- Asthma (19)
- Adverse event (19)
- Treatment Form (19)
- Diabetes Mellitus, Type 2 (17)
- Testosterone (14)
- Hypogonadism (14)
- Migraine Disorders (14)
- Sumatriptan (13)
- On-Study Form (13)
- Liver (13)
- Peritoneal Neoplasms (12)
- Cross-Over Studies (12)
- Clinical Chemistry Tests (12)
- Fallopian Tube Neoplasms (12)
- Gynecology (12)
- Hypertension (12)
- Ovarian Neoplasms (12)
- Pharmacogenetics (11)
- Consent Forms (11)
- Therapeutics (10)
- Concomitant Medication (10)
- Non Small Cell Lung Cancer (10)
- Parkinsons Disease (10)
- Disease (10)
- Urinalysis (9)
- Hypereosinophilic Syndrome (9)
- Contraceptives, Oral, Combined (9)
- Telemetry (8)
- Blood (8)
- Blood Pressure (8)
- Drug trial (8)
- Compliance (8)
- Random Allocation (7)
- Clinical Trial, Phase III (7)
- Type 2 Diabetes (7)
- Double-Blind Method (7)
- Placebos (6)
- Arthritis, Rheumatoid (6)
- Restless Legs Syndrome (6)
- Thyroid Hormones (6)
- Randomized Controlled Trial (6)
- Blood Glucose (6)
- Alcohol Drinking (6)
- Eligibility Determination (6)
- Glucose Tolerance Test (6)
- Medical Records (6)
- Pregnancy (5)
- Arthritis (5)
- Rheumatology (5)
- Biopsy (5)
- Diagnostic Imaging (5)
- Drug Administration Schedule (5)
- Eye Diseases (5)
- Macular Degeneration (5)
- Psychiatry (4)
- Risk Factors (4)
- Urine (4)
- Biological Markers (4)
- Premature Ejaculation (4)
- Drug-Related Side Effects and Adverse Reactions (4)
- Physical Examination (3)
- Atherosclerosis (3)
- Healthy Volunteers (3)
- End of Study (3)
- Alzheimer Disease (3)
- Pregnancy Tests (2)
- Rhinitis (2)
- Schizophrenia (2)
- Steroids (2)
- Bacterial Infections (2)
- Vaccines (2)
- Purpura, Thrombocytopenic, Idiopathic (2)
- Clinical Trial, Phase IV (2)
- Blood Specimen Collection (2)
- Body Temperature (2)
- Substance-Related Disorders (2)
- Measles-Mumps-Rubella Vaccine (2)
- Child (2)
- Adrenergic beta-2 Receptor Agonists (2)
- Transcriptome (2)
- Meals (2)
- Death (2)
- Demography (2)
Table of contents
Selected data models
You must log in to select data models for download or further analysis.
224 Search results.
Itemgroups: Administrative,Vital Signs,12-Lead ECG,Laboratory Results Data (Haematology) - Pre-Dose,Laboratory Results Data (Clinical Chemistry) - Pre-Dose,Urinalysis - Pre-Dose,Randomisation Number,Investigational Product,Treatment Confirmation,PET Scan (2),fMRI Scan - Post-PET Scan,PET Scan (3),Pharmacokinetics - Blood,Laboratory Results Data (Haematology) - 24hrs Post-Dose,Laboratory Result Data (Clinical Chemistry) - 24hrs Post-Dose,Urinalysis - 24hrs Post-Dose
Itemgroups: Pharmacogenetic Research,prior medication,baseline signs and symptoms
Itemgroups: Administrative Data,12-Lead ECG Abnormalities,Rhythm,P-Wave Morphology,Conduction,Myocardial Infarction,Depolarisation/Repolarisation (QRS-T),ECG, Other abnormalities
Itemgroups: Administrative Data,Adverse Event | Concomitant Medication | Evaluation
Itemgroups: Administrative,Date of Visit/ Assessment,Randomisation (only Session 1),Vital Signs,Sitting Vital Signs - Predose,Orthostatic Vital Signs - Predose (Reading 1) - Supine for 5 mins,Orthostatic Vital Signs - Predose (Reading 2) - Sitting for 2 mins ,Orthostatic Vital Signs - Predose (Reading 3) - Standing for 3 mins ,Orthostatic Vital Signs - Post Dose - Sitting,Orthostatic Vital Signs - 10 Hours (Reading 1) - Supine for 5 mins,Orthostatic Vital Signs - 10 Hours (Reading 2) - Sitting for 2 mins ,Orthostatic Vital Signs - 10 Hours (Reading 3) - Standing for 3 mins ,Pharmacokinetics Blood - Dosing Date and Time,Pharmacokinetics Blood,Investigational Product,Treatment Confirmation,12-Lead ECG (only Session 4)
Itemgroups: Date of Visit,Randomisation Number (Vsit 1),Vital Signs - Challenge Date and Time (Visit 1, 3, 5),Vital Signs - Start of Challenge (Visit 1, 3, 5),Nasal Inspection (Visit 1, 3, 5),Challenge Date and Time - Challenge (0 - 6 Hr) (Visit 1, 3, 5),Investigational Product (Dose) - Challenge Date and Time (Visit 1, 3, 5),Investigational Product - Date/time of dose (Visit 1, 3, 5),Investigational Product - Treatment Confirmation (Visit 1, 3, 5)
Itemgroups: Administrative,Investigational Product Day 1 - 7,Treatment Corfirmation Day 1 - 7,Carbon Monoxide Test - Day 6 PM,Urine Test for Drugs of Abuse,Urine Test for Drugs of Abuse ,Vital Signs - Day 7,12-Lead ECG - Day 7,12-Lead ECG Abnormalities - Day 7,12-Lead ECG Abnormalities - Day 7,Pulmonary Function Test - Day 7
Itemgroups: Date of visit,Investigational Product (Dose) (Part 2 Period 2),ECG,ECG - Day 2 Dose (Part 2 Period 2),ECG - Day 2 Dose (Part 2 Period 2,ECG - Day 3 Dose (Part 2 Period 2),ECG - Day 3 Dose (Part 2 Period 2),ECG - Day 4 Dose (Part 2 Period 2),ECG - Day 4 Dose (Part 2 Period 2),ECG - Day 5 Dose (Part 2 Period 2),ECG - Day 5 Dose (Part 2 Period 2),ECG - Day 6 Dose (Part 2 Period 2),ECG - Day 6 Dose (Part 2 Period 2),Vital Signs - Day 2 Dose (Part 2 Period 2),Vital Signs - Day 2 Dose (Part 2 Period 2),Vital Signs - Day 3 Dose (Part 2 Period 2),Vital Signs - Day 3 Dose (Part 2 Period 2),Vital Signs - Day 4 Dose (Part 2 Period 2),Vital Signs - Day 4 Dose (Part 2 Period 2),Vital Signs - Day 5 Dose (Part 2 Period 2),Vital Signs - Day 5 Dose (Part 2 Period 2),Vital Signs - Day 6 Dose (Part 2 Period 2),Vital Signs - Day 6 Dose (Part 2 Period 2),Pulmonary Function Tests - Day 2 Dose (Part 2 Period 2),Pulmonary Function Tests - 2 hours Post-Dose, Day 2 (Part 2 Period 2),Pulmonary Function Tests - Day 3 Dose (Part 2 Period 2),Pulmonary Function Tests - 2 hours Post-Dose, Day 3 (Part 2 Period 2),Pulmonary Function Tests - Day 4 Dose (Part 2 Period 2),Pulmonary Function Tests - 2 hours Post-Dose, Day 4 (Part 2 Period 2),Pulmonary Function Tests - Day 5 Dose (Part 2 Period 2),Pulmonary Function Tests - 2 hours Post-Dose, Day 5 (Part 2 Period 2),Pulmonary Function Tests - Day 6 Dose (Part 2 Period 2),Pulmonary Function Tests - 2 hours Post-Dose, Day 6 (Part 2 Period 2)
Itemgroups: Date of visit,Local Laboratory - Haematology (Part 2 Period 4),Local Laboratory - Haematology (Part 2 Period 4),Local Laboratory - Clinical Chemistry (Part 2 Period 4),Local Laboratory - Clinical Chemistry (Part 2 Period 4),Investigational Product (Dose) (Part 2 Period 4),ECG (Part 2 Period 4),ECG (Part 2 Period 4),Vital Signs (Part 2 Period 4),Vital Signs (Part 2 Period 4),Local Laboratory - Haematology (24Hr Lab) (Part 2 Period 4),Local Laboratory - Haematology (24 Hr Lab) (Part 2 Period 4),Local Laboratory - Clinical Chemistry (24 Hr Lab) (Part 2 Period 4),Local Laboratory - Clinical Chemistry (24 Hr Lab) (Part 2 Period 4),Pulmonary Function Tests (Part 2 Period 4),Pulmonary Function Tests (Part 2 Period 4)
Itemgroups: Date of Visit,Local Laboratory - Haematology (Period 1),Local Laboratory - Haematology (Period 1),Local Laboratory - Clinical Chemistry (Period 1),Local Laboratory - Clinical Chemistry (Period 1),Investigational Product (Dose) (Period 1),ECG (Period 1),Vital Signs (Period 1),Local Laboratory - Haematology (24Hr Lab) (Period 1),Local Laboratory - Haematology (24 Hr Lab) (Period 1),Local Laboratory - Clinical Chemistry (24 Hr Lab) (Period 1),Local Laboratory - Clinical Chemistry (24 Hr Lab) (Period 1),Pharmacokinetics Blood (Period 1),Pharmacokinetics Blood (Period 1),Pharmacokinetics Urine (Period 1),Pharmacokinetics Urine (Period 1),Summary Holter (Period 1),Summary Holter (Period 1) (Pre-Dose - 24 hours),Holter Abnormalities (Period 1),Holter Abnormalities (Period 1),Pulmonary Function Tests (Period 1)
Itemgroups: Date of visit,Investigational Product (Dose) (Part 2 Period 2),ECG (Part 2 Period 2),ECG (Part 2 Period 2),Vital Signs (Part 2 Period 2),Vital Signs (Part 2 Period 2),Pulmonary Function Tests (Part 2 Period 2),Pulmonary Function Tests (Part 2 Period 2),Local Laboratory - Haematology (24Hr Lab) (Part 2 Period 2),Local Laboratory - Haematology (24 Hr Lab) (Part 2 Period 2),Local Laboratory - Clinical Chemistry (24 Hr Lab) (Part 2 Period 2),Local Laboratory - Clinical Chemistry (24 Hr Lab) (Part 2 Period 2),Pharmacokinetics Blood (Part 2 Period 2),Pharmacokinetics Blood (Part 2 Period 2),Pharmacokinetics Urine (Part 2 Period 2),Pharmacokinetics Urine (Part 2 Period 2),Summary Holter (Part 2 Period 2),Summary Holter (Part 2 Period 2) (Pre-Dose - 24 hours),Holter Abnormalities (Part 2 Period 2),Holter Abnormalities (Part 2 Period 2)
Itemgroups: Date of Visit,Local Laboratory - Haematology (Period 3),Local Laboratory - Haematology (Period 3),Local Laboratory - Clinical Chemistry (Period 3),Local Laboratory - Clinical Chemistry (Period 3),Investigational Product (Dose) (Period 3),ECG (Period 3),Vital Signs (Period 3),Local Laboratory - Haematology (24Hr Lab) (Period 3),Local Laboratory - Haematology (24 Hr Lab) (Period 3),Local Laboratory - Clinical Chemistry (24 Hr Lab) (Period 3),Local Laboratory - Clinical Chemistry (24 Hr Lab) (Period 3),Pharmacokinetics Blood (Period 3),Pharmacokinetics Blood (Period 3),Pharmacokinetics Urine (Period 3),Pharmacokinetics Urine (Period 3),Summary Holter (Period 3),Summary Holter (Period 3) (Pre-Dose - 24 hours),Holter Abnormalities (Period 3),Holter Abnormalities (Period 3),Pulmonary Function Tests (Period 3)